• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Immediately early 2 (IE-2) and DNA polymerase SiRNA as virus-specific antiviral against novel transplacental cytomegalovirus strain ALL-03 in vitro
CONCLUSION: In conclusion, this study clearly highlighted the feasibility of RNAi as an alternative antiviral therapy that could lead to controlling the CMV infection.PMID:33640483 | DOI:10.1016/j.meegid.2021.104783
Source: Infection, Genetics and Evolution - February 28, 2021 Category: Genetics & Stem Cells Authors: Krishnan Nair Balakrishnan Ashwaq Ahmed Abdullah Jamilu Abubakar Bala Faez Firdaus Abdullah Jesse Che Azurahanim Che Abdullah Mustapha Mohamed Noordin Mohd Lila Mohd-Azmi Source Type: research

Herpesviruses and the microbiome
The focus of this article will be to examine the role of common herpesviruses as a component of the microbiome of atopic patients and to review clinical observations suggesting that atopic patients might be predisposed to more severe and atypical herpes-related illness because their immune response is biased toward a TH2 cytokine profile. Human populations are infected with 8 herpesviruses, including herpes simplex virus HSV1 and HSV2 (also termed HHV1 and HHV2), varicella zoster virus (VZV or HHV3), EBV (HHV4), cytomegalovirus (HHV5), HHV6, HHV7, and Kaposi sarcoma–associated herpesvirus (termed KSV or HHV8). Herpesviru...
Source: Journal of Allergy and Clinical Immunology - April 22, 2013 Category: Allergy & Immunology Authors: David H. Dreyfus Tags: Rostrum Source Type: research

Identification of KX2-391 as an inhibitor of HBV transcription by a recombinant HBV-based screening assay
This study used recombinant HBV encoding NanoLuc to screen anti-HBV compounds from 1827 US Food and Drug Administration approved compounds and identified several compounds that suppressed HBV infection. Among them, KX2-391, a non-ATP-competitive inhibitor of SRC kinase and tubulin polymerization, was identified as a lead candidate for an anti-HBV drug. Treatment of sodium taurocholate cotransporting polypeptide (NTCP) transduced-HepG2 (HepG2-NTCP) or primary human hepatocytes with KX2-391 suppressed HBV replication in a dose-dependent manner. The anti-HBV activity of KX2-391 appeared not to depend on SRC kinase activity be...
Source: Antiviral Therapy - June 16, 2017 Category: Virology Source Type: research